Perinatal Stem Cells
Research and Therapy
- 1st Edition - June 14, 2018
- Editors: Anthony Atala, Kyle J. Cetrulo, Rouzbeh R. Taghizadeh, Curtis L Cetrulo, Sean Murphy
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 2 0 1 5 - 6
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 2 0 6 3 - 7
Perinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePerinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal sources, such as amniotic fluid, placenta and placental membranes, the umbilical cord and Wharton’s jelly. It's compiled by leading experts in the field, offering readers detailed insights into sources of perinatal stem cells and their potential for disease treatment. Therapeutic applications of perinatal stem cells include the treatment of in utero and pregnancy related diseases, cardiac disease, liver disease, pulmonary disease, inflammatory diseases, for hematopoietic regeneration, and for neural protection after stroke or traumatic brain injury.
In addition, the rapid advance in clinical translation and commercialization of perinatal stem cell therapies is highlighted in a section on Clinical and Industry Perspective which provides insight into the new opportunities and challenges involved in this novel and exciting industry.
- Explores current clinical and pre-clinical application of stem cells derived from perinatal sources
- Offers detailed insight into sources of perinatal stem cells and their potential for disease treatment
- Discusses progress in the manufacturing, banking and clinical translation of perinatal stem cells
- Edited by a world-renowned team to present a complete story of the development and promise of perinatal stem cells
Advanced students and researchers in stem cell biology, regenerative medicine and tissue engineering, and developmental biology
Section I. Amniotic Fluid-Derived Stem Cells
1. In utero therapy for congenital disorders using amniotic fluid stem cells
2. The Amniotic Fluid Stem Cell Secretome: at the Heart of Regeneration
3. Transplantation of Amniotic Fluid-Derived Neural Stem Cells
4. Stroke therapy: the potential of amniotic fluid-derived stem cells
5. Vascular formation by human perinatal stem cells
6. Amniotic Fluid Stem Cells for Kidney Regeneration
Section II. Placental and Placental Membrane-Derived Stem Cells
7. Placental mesenchymal stem cells for cellular cardiomyoplasty
8. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use
9. Defining the fetal stem cell niche in the human placenta
10. Banking placental tissue hematopoietic stem cells and mesenchymal stem cells for clinical use
11. Immuno-modulatory mechanisms of placental stem cells
12. Amnion Membrane Allograft for Regenerative Medicine
13. Perinatal cells and biomaterials for wound healing
14. Placental Stem Cells
15. Therapeutic Effect of Extracellular Vesicles Derived from Adult/Perinatal Human Mesenchymal Stem Cells
Section III. Umbilical Cord-Derived Cells
16. Ex-vivo Expansion of Cord Blood Stem Cells
17. Cord Blood Transplantation: Therapeutic Use of Perinatal Stem Cells
18. Autologous Human Cord Blood as a Treatment for Traumatic Brain Injury in Children
19. Phenotypic and Functional Characterization Perinatal Stem Cells Isolated from Umbilical Cord Tissue
20. Mesenchymal stromal cells from Wharton’s jelly (WJ-MSCs): coupling their hidden differentiative program with their frank immunomodulatory phenotype
21. Regeneration of ischemic cardiovascular damage using Jelly Wharton as an unlimited source of therapeutic stem cells
22. Phenotype with Focused Paracrine Fractions: Effecting Future Phenotype with Focused Paracrine Fractions
Section IV. Clinical and Industry Perspective
23. Clinical Translation of Perinatal Stem Cell Therapy
24. Current Clinical Trials utilizing Perinatal Stem Cells – A Review
25. Review Of Processing Technology and Techniques for Perinatal Stem Cells Banking And Clinical Applications
26. Clinical Development And Commercialization Of Placenta-Derived Cell Therapy
27. How the patent landscape has changed
28. The Need for Better Assays to Predict the Effectiveness of Tissue Stem Cell Treatments
- No. of pages: 418
- Language: English
- Edition: 1
- Published: June 14, 2018
- Imprint: Academic Press
- Hardback ISBN: 9780128120156
- eBook ISBN: 9780128120637
AA
Anthony Atala
Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering.
Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.
Affiliations and expertise
G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine; W. Boyce Professor and Chair, Department of Urology, and G. Link Professor and Director, Wake Forest Institute for Regenerative Medicine, Wake Forest University. Winston Salem, North Carolina, USAKC
Kyle J. Cetrulo
Affiliations and expertise
Chief Executive Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USART
Rouzbeh R. Taghizadeh
Affiliations and expertise
Co-Founder, Chief Scientific Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USACC
Curtis L Cetrulo
Affiliations and expertise
Assistant Professor, Surgery, Harvard Medical School, Plastic and Reconstructive Surgery, Surgery, Massachusetts General Hospital, USASM
Sean Murphy
Affiliations and expertise
Assistant Professor, Wake Forest Institute for Regenerative Medicine, USARead Perinatal Stem Cells on ScienceDirect